- Home
- AVIR vs MMD Comparison
AVIR vs MMD Comparison
Compare AVIR & MMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- MMD
- Stock Information
- Founded
- AVIR 2012
- MMD 2012
- Country
- AVIR United States
- MMD United States
- Employees
- AVIR N/A
- MMD N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- MMD Investment Managers
- Sector
- AVIR Health Care
- MMD Finance
- Exchange
- AVIR Nasdaq
- MMD Nasdaq
- Market Cap
- AVIR 290.4M
- MMD 274.9M
- IPO Year
- AVIR 2020
- MMD N/A
- Fundamental
- Price
- AVIR $2.97
- MMD $15.44
- Analyst Decision
- AVIR Hold
- MMD
- Analyst Count
- AVIR 1
- MMD 0
- Target Price
- AVIR $6.00
- MMD N/A
- AVG Volume (30 Days)
- AVIR 223.7K
- MMD 74.7K
- Earning Date
- AVIR 11-06-2025
- MMD 01-01-0001
- Dividend Yield
- AVIR N/A
- MMD 4.88%
- EPS Growth
- AVIR N/A
- MMD N/A
- EPS
- AVIR N/A
- MMD N/A
- Revenue
- AVIR N/A
- MMD N/A
- Revenue This Year
- AVIR N/A
- MMD N/A
- Revenue Next Year
- AVIR N/A
- MMD N/A
- P/E Ratio
- AVIR N/A
- MMD N/A
- Revenue Growth
- AVIR N/A
- MMD N/A
- 52 Week Low
- AVIR $2.46
- MMD $14.30
- 52 Week High
- AVIR $4.10
- MMD $17.67
- Technical
- Relative Strength Index (RSI)
- AVIR 33.48
- MMD 75.82
- Support Level
- AVIR $2.84
- MMD $15.25
- Resistance Level
- AVIR $3.33
- MMD $14.66
- Average True Range (ATR)
- AVIR 0.14
- MMD 0.15
- MACD
- AVIR -0.04
- MMD 0.06
- Stochastic Oscillator
- AVIR 18.98
- MMD 94.80
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
NYLI MacKay DefinedTerm Muni Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company predominantly invests in municipal bonds, the interest on which is, in the opinion of bond counsel to the issuers, generally excludable from gross income for regular U.S. Federal income tax purposes.